US stock futures steady after Wall St soars on dovish Powell; Nvidia earnings due
On Thursday, Sutro Biopharma (NASDAQ: NASDAQ:STRO) experienced a shift in stock rating as JMP analysts downgraded the company from Market Outperform to Market Perform. This decision was made after the company announced significant changes to its drug development strategy, including the discontinuation of its lead program, luvelta. InvestingPro data shows the stock has declined over 68% in the past year, with two analysts recently revising earnings estimates downward.
The company revealed these changes on Wednesday, noting that it would be reducing its workforce by nearly 50%. Alongside the cessation of the luvelta program, which was previously central to the company’s valuation, Sutro Biopharma is now refocusing its efforts on three preclinical candidates. Despite the company’s strong cash position, with $316.9 million on hand, resulting in an approximate enterprise value (EV) of $212 million, analysts at JMP have removed their price target for the stock. According to InvestingPro analysis, while the company maintains more cash than debt and a healthy current ratio of 3.09, it’s quickly burning through its cash reserves. Get detailed insights and 13 additional ProTips with an InvestingPro subscription.
The company’s management has outlined its future plans, which include initiating clinical trials for STRO-004, a tissue factor-targeting agent, in the second half of 2026. Additionally, a new drug application (IND) for STRO-006 is anticipated in mid-2026. Sutro Biopharma also expects progress from its partners, Ipsen (EPA:IPN) and Astellas, who are advancing earlier-stage products.
However, despite these developments, JMP analysts believe that the shares of Sutro Biopharma are likely to align with market performance until potentially differentiating data from the STRO-004 trials becomes available in 2026. The refocusing on the three preclinical candidates marks a significant pivot in the company’s strategy following the termination of the luvelta program.
In other recent news, Sutro Biopharma announced a strategic shift in its focus toward next-generation antibody drug conjugates (ADCs), resulting in a nearly 50% reduction in its workforce and plans to close its internal GMP manufacturing facility by the end of 2025. The company is prioritizing its lead program, STRO-004, which targets solid tumors and is expected to enter clinical trials in the latter half of 2025. Sutro also reported a strong financial position with cash and marketable securities totaling $316.9 million as of December 31, 2024, projecting a cash runway extending into the fourth quarter of 2026. Additionally, Jane Chung has been appointed as the new CEO, succeeding Bill Newell.
Meanwhile, Strongpoint reported a 3% increase in revenue for Q4 2024, totaling DKK 9 million, with significant growth in Sweden. The company also improved its EBITDA to NOK 5 million from a previous loss, maintaining a robust cash position of NOK 82 million. Strongpoint’s strategic expansion of its self-checkout solutions in Europe, particularly in the UK, is notable, despite facing challenges in Spain. The company has also formed a multifaceted partnership with Vision Group, enhancing its digital retail solutions. These developments highlight recent shifts and financial updates from both Sutro Biopharma and Strongpoint.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.